Elizeu/sandbox/citocromo c

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
m
Line 1: Line 1:
-
[[User: Julie Langlois/PsaA]]
 
Line 11: Line 10:
== Overview ==
== Overview ==
-
[[Image:streptococcus pneumoniae.jpg | 250px|thumb| ''Streptococcus pneumoniae'' <ref>http://www.sciencephoto.com/images/download_lo_res.html?id=662360183</ref>]] PsaA (Pneumococcal surface antigen A) is a high affinity substrate-binding lipoprotein <ref name="ref5">http://www.uniprot.org/uniprot/P0A4G2</ref> detected on all known serotypes of [https://en.wikipedia.org/wiki/Streptococcus_pneumoniae ''Streptococcus pneumonia'']. It facilitates the acquisition of Mn<sup>2+</sup> by being part of the cell's [https://de.wikipedia.org/wiki/ABC-Transporter ABC (ATP binding cassette) transporter] and plays a major role in pneumococcal attachment to the host cell and [https://en.wikipedia.org/wiki/Virulence virulence] <ref>PMID:25786639</ref>.
+
'''[[Image:streptococcus pneumoniae.jpg | 250px|thumb| ''Streptococcus pneumoniae'' <ref>http://www.sciencephoto.com/images/download_lo_res.html?id=662360183</ref>]] PsaA (Pneumococcal surface antigen A) is a high affinity substrate-binding lipoprotein <ref name="ref5">http://www.uniprot.org/uniprot/P0A4G2</ref> detected on all known serotypes of [https://en.wikipedia.org/wiki/Streptococcus_pneumoniae ''Streptococcus pneumonia'']. It facilitates the acquisition of Mn<sup>2+</sup> by being part of the cell's [https://de.wikipedia.org/wiki/ABC-Transporter ABC (ATP binding cassette) transporter] and plays a major role in pneumococcal attachment to the host cell and [https://en.wikipedia.org/wiki/Virulence virulence] <ref>PMID:25786639</ref>.'''
Line 117: Line 116:
PsaA is being actively evaluated as a component of a vaccin in formulations composed of pneumococcal common proteins. PsaA is a component of a vaccin because this protein is immunogenic and stimulates an increase in [https://en.wikipedia.org/wiki/Antibody antibody] production when the nasopharynx is naturally colonized. PsaA has been expressed as an ''E.coli'' recombinant protein, purified, and evaluated in a phase one clinical trial.
PsaA is being actively evaluated as a component of a vaccin in formulations composed of pneumococcal common proteins. PsaA is a component of a vaccin because this protein is immunogenic and stimulates an increase in [https://en.wikipedia.org/wiki/Antibody antibody] production when the nasopharynx is naturally colonized. PsaA has been expressed as an ''E.coli'' recombinant protein, purified, and evaluated in a phase one clinical trial.
Progress in vaccine development is most advanced for ''Streptococcus pneumoniae''. Indeed, there is a seven-valent capsular-conjugate vaccine, [https://en.wikipedia.org/wiki/Pneumococcal_conjugate_vaccine PREVNAR®] but it is rather non efficient for otitis media.<ref>PMID:11176564</ref> PsaA has been shown to be an effective vaccine in animal models at preventing Streptococcus pneumoniae infection.
Progress in vaccine development is most advanced for ''Streptococcus pneumoniae''. Indeed, there is a seven-valent capsular-conjugate vaccine, [https://en.wikipedia.org/wiki/Pneumococcal_conjugate_vaccine PREVNAR®] but it is rather non efficient for otitis media.<ref>PMID:11176564</ref> PsaA has been shown to be an effective vaccine in animal models at preventing Streptococcus pneumoniae infection.
-
 
+
<math>Insert formula here</math>
==References==
==References==
<references/>
<references/>

Revision as of 20:34, 31 January 2017


NCBI Accession: P42363.1

Uniprot Accesion: POA4G2

PDB ID: 3ZK7

3D structure of PsaA in the metal-free, open state (PDB: 3zk7)

Drag the structure with the mouse to rotate
Personal tools